Brief: Pharvaris To Highlight Positive Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks At AAAAI Annual Meeting
24/02/2023 11:55
Feb 24 (Reuters) - Pharvaris NV PHVS.O :
* PHARVARIS TO HIGHLIGHT POSITIVE PHASE 2 DATA FROM RAPIDE-1
STUDY
OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS AT AAAAI
ANNUAL MEETING
Source text for Eikon: ID:nGNX86024z
Further company coverage: PHVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharvaris NV
See all newsSwitzerland's Pharvaris Q1 loss per share narrows
Brief: Pharvaris Announces Pricing Of $115 Million Underwritten Offering Of Ordinary Shares
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's